Clinical Trial

Phase 1 Single Ascending Dose Study

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 18, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.
Trial Details
NCT Number NCT06934941
Lead Sponsor Neuramedy Co. Ltd.
Collaborators: Seoul National University Hospital
Conditions Healthy Subjects
Enrollment 36 participants
Start Date 2024-11-25
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-18